Cyclezyme (CYCLE) Investor update summary
Event summary combining transcript, slides, and related documents.
Investor update summary
27 Feb, 2026Partnership expansion and project preparation
Collaboration with a leading recycling and environmental technology partner is deepening to prepare a major joint development project targeting enzymatic recycling of polyester-based plastic streams at a pre-industrial scale.
Successful feasibility study demonstrated strong results on real plastic flows, supporting the move toward larger-scale development.
Significant volumes of low-grade PET, currently incinerated, have been identified as suitable for enzymatic recycling, offering both climate benefits and market potential.
Project scope and technical focus
The upcoming project will include in-depth analysis of process side streams and residues to optimize the recycling process and inform future techno-economic assessments.
Production of customer samples is central, enabling direct engagement with future users and adaptation to market quality requirements.
Stakeholder engagement and updates
A digital update for shareholders and stakeholders is scheduled for February 5 at 18:45, featuring a company status update and Q&A session.
The meeting will cover ongoing customer projects, partnerships, and next steps in commercial development, with a recorded version available afterward.
Latest events from Cyclezyme
- Revenue growth and reduced losses mark a pivotal year, with strong partner-driven project momentum.CYCLE
Q4 202527 Feb 2026 - Granted patent, industrial scale-up, and improved liquidity mark a pivotal growth phase.CYCLE
Q3 202514 Nov 2025 - Scalable enzyme technology revolutionizes PET recycling, meeting regulatory and market needs.CYCLE
Investor Update12 Sep 2025 - Advanced toward commercialization with new patent, paid pilot, and strong liquidity.CYCLE
Q2 202529 Aug 2025 - Breakthrough in PET recycling technology and strong liquidity position despite ongoing losses.CYCLE
Q3 202413 Jun 2025 - Breakthrough in PET recycling achieved; losses widen but liquidity remains strong.CYCLE
Q2 202413 Jun 2025 - Cyclezyme advances commercialization with new partnerships, improved results, and solid funding.CYCLE
Q1 20256 Jun 2025 - No revenue but key breakthroughs and partnerships position Cyclezyme for EU-driven growth.CYCLE
Q4 20246 Jun 2025